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ReportAntibodies against -Amyloid
Slow Cognitive Decline
in Alzheimer’s Disease
behaviors (Schenk et al., 1999; Bard et al., 2000; Janus
et al., 2000; Morgan et al., 2000; De Mattos et al., 2001).
In a human patient with AD, immunization against
-amyloid was associated with sizable brain areas de-
void of -amyloid, reduced neuritic pathology, reduced
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Dominique J.F. de Quervain, astrocytosis, and microglial cells filled with -amyloid
(Nicoll et al., 2003), as predicted by previous immuniza-Marc Hofmann, Alessia Maddalena,
Andreas Papassotiropoulos, and Roger M. Nitsch* tion experiments in transgenic mice.
To test whether active immunization can slow the pro-Division of Psychiatry Research
University of Zurich gression of dementia in patients with AD, a recent
multicenter study was initiated, but active dosing of theAugust Forel Strasse 1
8008 Zurich vaccine was suspended after the transient occurrence
of clinical signs of aseptic meningoencephalitis in 6%Switzerland
of the cases (Schenk, 2002; Orgogozo et al., 2003). After
suspension of dosing, we continued to follow up our
cohort of 30 AD patients who participated in this study.Summary
Patients with a clinical diagnosis of mild to moderate
AD had received active prime and booster immuniza-To test whether antibodies against -amyloid are ef-
fective in slowing progression of Alzheimer’s disease, tions with preaggregated A42(QS-21) (n24) or placebo
(n 6) in a double-blind, randomized study design (Hockwe assessed cognitive functions in 30 patients who
received a prime and a booster immunization of aggre- et al., 2002; Schenk, 2002; Orgogozo et al., 2003). By
using a specific and sensitive tissue amyloid plaquegated A42 over a 1 year period in a placebo-controlled,
randomized trial. Twenty patients generated antibod- immunoreactivity (TAPIR) assay, we observed the sus-
tained generation of antibodies against brain -amyloidies against-amyloid, as determined by tissue amyloid
plaque immunoreactivity assay. Patients who gener- plaques in 20 of our 30 patients (Hock et al., 2002). To
determine whether these antibodies were associatedated such antibodies showed significantly slower
rates of decline of cognitive functions and activities with modifications of the clinical course of AD, we tested
cognitive functions and capacities of daily living of theof daily living, as indicated by the Mini Mental State
Examination, the Disability Assessment for Dementia, patients at baseline (n  30) and during a 1 year period
(n  28, due to two dropouts).and the Visual Paired Associates Test of delayed recall
from the Wechsler Memory Scale, as compared to
patients without such antibodies. These beneficial
clinical effects were also present in two of three pa- Results
tients who had experienced transient episodes of im-
munization-related aseptic meningoencephalitis. Our Human Antibodies Recognized Brain
-Amyloid Plaquesresults establish that antibodies against -amyloid
plaques can slow cognitive decline in patients with Twenty of thirty patients in this study generated antibod-
ies that specifically recognized -amyloid plaques onAlzheimer’s disease.
brain tissue sections obtained from transgenic mice ex-
pressing in brains both human APP with the SwedishIntroduction
mutation and human presenilin 1 (PS1) with the M146L
mutation (APPSwxPS1M146L) (Figure 1; Holcomb et al.,-amyloid is a major histopathological hallmark of Alz-
heimer’s disease (AD) (National Institute on Aging, 1997). 1998). The ten other patients did not generate such anti-
bodies, or had very low serum level at baseline withIt is associated with age-related cognitive decline, neu-
rotoxicity, and the formation of neurofibrillary tangles unchanged levels during the study. Together, this group
(NFT) (Naslund et al., 2000; Chen et al., 2000; Geula et of patients (n 9 observed cases at month 12) was used
al., 1998; Go¨tz et al., 2001; Lewis et al., 2001). Therefore, as the control group for comparisons. The presence, or
several -amyloid-lowering strategies are currently de- the absence, of the antibodies against -amyloid was
veloped for clinical use. These include inhibition of the unrelated to the occurrence of aseptic meningoenceph-
generation of amyloid -peptide (A) with - and alitis in a total of three patients in our cohort. Confocal
-secretase inhibitors, prevention of A aggregation, microscopy images of -amyloid plaques stained with
and immunization against -amyloid (Citron, 2002; human immune sera or immune CSF showed close to
Weiner and Selkoe, 2002; Sigurdsson et al., 2002; complete overlap in staining obtained with both the
Gandy, 2002). Both passive and active immunization of monoclonal antibody 4G8 against A and with Thioflavin
transgenic mice against-amyloid can reverse neuropa- S. The overlap in staining with Thioflavin S indicated
thology and improve pathologic learning and memory that these human antibodies recognized bona fide brain
-amyloid plaques. To score the ability of the sera to
recognize -amyloid plaques, we used our TAPIR assay*Correspondence: nitsch@bli.unizh.ch (R.M.N.), chock@bli.unizh.ch
(C.H.) (Hock et al., 2002).
Neuron
548
Figure 1. Confocal Immunofluorescence Im-
age of -Amyloid Plaques Stained by Human
Antibodies against -Amyloid Obtained from
a Patient with AD Who Participated in This
Study
(A) Human immune serum with antibodies
against -amyloid.
(B–F) Triple-stained -amyloid plaque.
(B) Human immune CSF, red.
(C) Monoclonal antibody 4G8, blue.
(D) Human immune CSF and 4G8, purple.
(E) Thioflavin S, green.
(F) Human immune CSF and thioflavin S,
yellow.
Scale bar equals 20 m.
Slowed Decline of Cognitive Functions ity Assessment for Dementia (DAD) rating scale by inter-
viewing caregivers in a double-blinded manner (Gauthierand Capacities of Daily Living
AD patients who generated antibodies against -amy- et al., 1997). The DAD assesses activities of daily living
including initiation, planning, and organization; perfor-loid (n  19) performed markedly better on the Mini
Mental State Examination (MMSE) 8 months and 1 year mance in eating, bathing, grooming, dressing, and toilet-
ing; and telephone communication, paying bills, cook-after the immunization, as compared to control patients
(n  9, p  0.008, ANOVA) (Figure 2A). As compared to ing, and shopping. Performance in the DAD was
significantly better in patients who generated antibodiesbaseline, the patients who generated antibodies against
-amyloid remained unchanged after 1 year (1.4 3.5, against -amyloid, as compared to control patients (Fig-
ure 2B). After 12 months, patients who generated anti-mean SD n.s., median1.0). Patients in the control
group worsened significantly by 6.3  4.0 MMSE bodies against -amyloid declined by 2.9  3.8 of 40
points on the DAD, as compared to 8.7  10.0 inpoints (mean SD, median5.0; p 0.01, Wilcoxon).
This magnitude of progression of dementia is clinically control patients (p  0.030, ANOVA) or, in percent of
applicable questions, by 6.1%  9.0% versusrelevant, and it is somewhat higher than rates of decline
known for the natural history of AD of3.9  3.7 MMSE 20.1%  23.4%, respectively (p  0.039, ANOVA).
Thus, the cognitive stabilization translated into rele-points per year, but both our mean and median values
are well within one standard deviation of published data vance for daily life.
(Morris et al., 1993). In contrast, the clinical stabilization
in the group of patients who generated antibodies Relation of Clinical Outcome to the Increase
in TAPIR Scoresagainst -amyloid differed markedly from the known
natural history of AD (Morris et al., 1993). To determine whether the clinical outcome was related
to TAPIR scores, we grouped the patients according toTo determine whether beneficial effects were also
noted by the patients’ caregivers, we applied the Disabil- the magnitude of increases in TAPIR scores and ob-
-Amyloid Antibodies Slow Decline in Alzheimer’s
549
Figure 2. The Generation of Antibodies
against -Amyloid Was Associated with
Slowed Declines in Cognitive Functions and
Activities of Daily Living
AD patients who generated antibodies
against -amyloid (filled symbols, solid lines)
were compared to patients without this im-
mune response (controls, open symbols,
dashed lines).
(A) MMSE scores of dementia severity. AD
patients who generated antibodies against
-amyloid (n  19) performed significantly
better (*p  0.008, ANOVA) than the controls
(n  9).
(B) DAD scores of activities of daily living.
Patients who generated antibodies against
-amyloid (n  19) performed significantly
better (*p  0.030, ANOVA) than control pa-
tients (n  9); in percent of applicable ques-
tions, patients who generated antibodies
against-amyloid declined by6.1% 9.0%
versus 20.1%  23.4% decline of controls
after 12 months (p  0.039, ANOVA).
(C) The magnitude of the immune response,
as defined by increases in TAPIR scores, was
related to the clinical outcome. Whereas con-
trol patients without increases in TAPIR
scores (n  9) worsened, patients with inter-
mediate increases (n 13) declined only mar-
ginally, and patients with strong increases
(n  6) remained stable (p  0.008, Kruskal-
Wallis test; *p  0.021, **p  0.004, U tests
versus controls).
(D) Prevention of disease progression. Upon
the generation of antibodies against
-amyloid, significantly more patients did not
progress to severe dementia (MMSE 14). In
contrast, the vast majority of control patients
had progressed to severe dementia (*p 
0.01, 2  7.25, d.f.  1).
(E) Cognitive stabilization. MMSE scores
were unchanged (3) or higher in 12 of 19 patients who generated antibodies against -amyloid (solid bar) in contrast to 2 of 9 control patients
(open bar) (*p  0.05, 2  4.09, d.f.  1).
(F) Preserved hippocampal function tested by the WMS Visual Paired Associates Test of delayed recall. Only two-thirds of the study patients
in either group were able to complete this task. Performance of the patients who generated antibodies against -amyloid (n  13) was
significantly better (*p  0.029, ANOVA) as compared to control patients (n  5).
tained the following three groups: no increase (n  9), -amyloid had progressed to severe dementia (p 0.01,
2  7.25, d.f.  1; Figure 2D). Moreover, 21% (4 of 19)intermediate increase (n 13), and strong increase (n
6) (Figure 2C). Whereas patients with no increases in of patients in this group had improved MMSE scores, as
compared to none in the control group. When cognitiveTAPIR scores worsened markedly, patients with inter-
mediate increases declined only marginally, and pa- stabilization was defined by unchanged (3 points) or
higher MMSE scores, 63% (12 of 19) of the patientstients with strong increases remained stable (p 0.008,
Kruskal-Wallis test). These data show a dose-response who generated antibodies against -amyloid remained
stable, as compared to 22% (2 of 9) in the control grouprelationship between the increase in serum antibodies
against -amyloid plaques and the clinical outcome. (p  0.05, 2  4.09, d.f.  1; Figure 2E).
Patients with strong increases in TAPIR scores were
essentially protected from disease progression. Nota-
Preserved Hippocampal Function
bly, two patients in this group improved to MMSE scores
Thirteen of twenty of the patients who generated anti-
of 28 and 30, back from 25 and 24 at baseline, respec-
bodies against -amyloid and 5 of 10 of the control
tively.
patients were able to complete the Visual Paired Associ-
ates Test of delayed recall from the Wechsler Memory
Scale. This task is a demanding test of hippocampalPrevention of Disease Progression
At baseline, only patients with mild to moderate demen- memory function (Wechsler, 1987). The reasons for not
completing (n 12) this test included inabilities to followtia (MMSE 16–26) were included in the study. After 1
year, 67% (6 of 9) of the control patients had progressed instructions or to learn items for recall and refusal. Upon
generation of antibodies against -amyloid, perfor-to severe dementia (MMSE 14). In contrast, only 16%
(3 of 19) of patients who generated antibodies against mance of the subset of patients who completed this
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TAPIR Assay Predicts Clinical Outcome
If binding to, and removal of, brain -amyloid is a thera-
peutic principle in AD, selective antibodies against
-amyloid should have stronger protective effects than
anti-A antibodies without the ability to bind -amyloid.
Indeed, we observed no significant differences in clinical
measures, cognitive performance, or neuropsychologi-
cal tests when ELISA titers of antibodies against A
peptides were used to differentiate responders from
nonresponders (p 	 0.05 in all tests). Moreover, two
patients with high ELISA titers but with low TAPIR scores
did not experience beneficial clinical effects, but three
patients with high TAPIR scores and with low, ELISA
titers were protected against disease progression. In
addition, there were no stable or improved patients with
high ELISA titers and low TAPIR scores, and there were
no worsened patients with high TAPIR scores and low
ELISA titers (p  0.025, 2  5.0; d.f.  1).
Antibodies against -Amyloid
Can Reach the Brain
We had available 20 paired CSF samples obtained both
at baseline and after 1 year. We found that immune CSF
of four patients contained antibodies against -amyloid
(Figure 1B), demonstrating the principal ability for the
antibodies to reach the CSF compartment. CSF/serum
ratios for albumin were normal in the patients with CSF
Figure 3. Sustained Increases in Serum Antibodies antibodies against -amyloid; presence of oligoclonal
Increases in TAPIR scores (n  20; filled symbols, solid line) were bands in CSF was observed in one patient. Our data
associated with long-lasting increases in serum IgG (A) and IgM (B) favor passage of antibodies across the blood-brain bar-
antibodies against A42 (*p  0.005 and p  0.0001, ANOVA). No rier, irrespective of its integrity, over intrathecal produc-changes in anti-A42-IgG or IgM in the control group (n  10; open
tion, as an explanation for antibody presence in CSF.symbols, dashed line).
The absence of either increased CSF cell counts or in-
creased CSF IgG indices imply that generation of anti-
bodies against -amyloid is not associated with chronic
test was significantly better (p  0.029, ANOVA), as
brain inflammation, although our 1 year CSF data can
compared to control patients (Figure 2F).
not rule out transient inflammatory episodes during ear-
lier time points within the study period.
Other Neuropsychological Tests
Unchanged Plasma and CSF Levels of AThe generation of antibodies against -amyloid was as-
In our patients, the generation of antibodies againstsociated with trends toward better test scores in other
-amyloid was not associated with major changes inassessments including the ADAS-Cog (with antibodies:
either CSF levels of A40 and A42 (Figures 4A and 4B)5.5  6.8, n  17 versus 7.8  5.2 in controls, n 
or in plasma levels of A42 (Figure 4C), arguing against6), naming (0.1  0.7, n  19 versus 0.7  1.0, n  9),
the possibility that sequestration of serum A is an un-verbal fluency (3.6  5.1, n  18 versus 5.9  4.3,
derlying principle of the therapeutic effects observedn  8), and CGIC (0.1  0.7, n  18 versus 1.1 
here. We do not know whether brain -amyloid load was1.0, n  8).
reduced in our study patients; in vivo imaging tech-
niques will be required to answer this question.
Sustained Increases in Serum Antibodies
against A Discussion
The group of patients who generated antibodies against
-amyloid showed a marked and long-lasting increase Here we report the results of our TAPIR analysis applied
to the Zurich cohort of 30 patients who participated inin serum antibodies against aggregated A42 in both IgG
(Figure 3A) and IgM (Figure 3B) classes as measured by a multicenter trial of -amyloid immunization. We ob-
served slowed cognitive decline in AD patients who gen-ELISA (p  0.005 and p  0.0001, ANOVA, two factors,
repeated measurements). Titers of both anti-A42-IgG erated antibodies against -amyloid plaques. Whereas
cognition of patients who did not generate such antibod-and anti-A42-IgM increased within the month after the
prime injection, attained a maximum within the month ies worsened, patients with intermediate increases in
such antibodies declined only marginally, and patientsafter the booster injection, and remained high until
month 12. These sustained increases could be related with strong increases remained clinically and cognitively
stable. The clinical stabilization was further substanti-to the long-term stability of the A42 aggregates use as
the vaccine. ated by significantly better performance in activities of
-Amyloid Antibodies Slow Decline in Alzheimer’s
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adequately by preparations of synthetic A on ELISA
plates. Together, the data underscore the importance
of using appropriate assays for antibody analyses, and
they suggest using TAPIR scores instead of ELISA titers
for the analysis of responders. These data also demon-
strate the necessity for carefully selecting therapeuti-
cally relevant epitopes within -amyloid and its constit-
uents for the future development of immunotherapy
for AD.
The observed clinical differences among AD patients
with and without an immune response were unrelated to
the AChEI treatments, because patients in both groups
were on stable dosages of AChEI before and during this
trial. These data therefore support the possibility that
the therapeutic effects of antibodies against -amyloid
and AChEI are additive. For the formal test of this possi-
bility, however, control groups without AChEI treatments
are required. Other factors that could potentially affect
rates of progression of dementia, including age, gender,
medication, and head trauma, were either excluded by
the selection criteria or were distributed evenly among
the groups. The ApoE genotype affects the risk for get-
ting AD as well as the age of onset, but not the rate of
cognitive decline once the disease has started (Grow-
don et al., 1996). Nevertheless, the distribution of the
common ApoE genotypes was equal among the groups
(p  0.114, 2  2.5; d.f.  1 for genotypes, and p 
0.438, 2  0.602; d.f.  1 for allele frequencies), and
there was no carrier of an ApoE
2 allele in our cohort.
During the course of the AN1792 multicenter trial, 6%
of the study patients developed clinical signs of aseptic
meningoencephalitis (Schenk, 2002; Orgogozo et al.,
2003), and they were generally treated with corticoste-
roids. These signs did not correlate with the generation
of antibodies against -amyloid. Moreover, occurrence
of aseptic meningoencephalitis did not predict clinical
outcome: two patients with aseptic meningoencephali-
tis and who generated antibodies against -amyloid inFigure 4. No Differences in CSF or Plasma Levels of A
our cohort remained cognitively stable 1 year after thePatients who generated antibodies against -amyloid (filled circles)
immunizations, despite the transient and reversible dropas compared to control patients (open circles).
(A) CSF levels of A40. during the acute symptoms. On the other hand, demen-
(B) CSF levels of A42. tia severity in one other meningoencephalitis patient
(C) Plasma levels of A42 (means  SEM, n  20 patients who without antibodies against -amyloid continuously de-
generated antibodies against -amyloid, n 10 control patients, n.s.). clined after recovery from the acute symptoms. These
data imply the possibility that the beneficial effects of
antibodies against -amyloid on cognitive functions are
daily living and by tests of hippocampal memory func- maintained even after transient episodes of postvacci-
tions. These data establish the possibility that antibod- nation aseptic meningoencephalitis.
ies against-amyloid are effective in halting the progres- Passive immunization of mice with antibodies against
sion of AD. soluble A resulted in increased plasma and CSF levels
Despite the fact that the TAPIR scores were statisti- of A within 3 days (Dodart et al., 2002; De Mattos et
cally correlated with ELISA titers of serum antibodies al., 2002), suggesting that antibody binding to plasma
against A42 (rs  0.700, p  0.001), the TAPIR scores A leads to its sequestration, followed by efflux of A
predicted therapeutic outcome, whereas ELISA did not. from brain to plasma. Other data show the importance
Together with our subgroup of patients with discrepant of high-affinity binding of antibodies to Fc receptors for
TAPIR scores and ELISA titers, these data suggest that removal of -amyloid from mouse brain, suggesting Fc
the degree of selectivity of the antibodies for bona fide receptor-mediated uptake of -amyloid by macro-
-amyloid is an important determinant for the clinical phages or microglia (Bard et al., 2003). Our data argue
efficacy of antibodies in AD. The difference between against sequestration as an underlying principle of the
TAPIR and ELISA scores could be related to important observed therapeutic effects, but the antibodies against
qualitative characteristics of the antibodies with respect -amyloid reported here are substantially different than
to epitope recognition, affinity, and avidity of the binding those used in the mouse studies, because of their rela-
reaction with -amyloid plaques in the physiologic brain tive selectivity for structural epitopes in -amyloid in
plaques (Hock et al., 2002).environment. These conditions may not be mimicked
Neuron
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the ELAN/Wyeth-Ayerst AN1792(QS-21) Phase 2A multicenter trialHow do the results of this study affect the status of
prior to unblinding of both treatment status and antibody responses.the amyloid cascade hypothesis of AD? Current versions
The study was approved by the ethics committee; written, informedof this hypothesis claim a primary role of -amyloid in
consent was obtained from all patients and caregivers. The clinical
the pathogenesis of AD (Steiner and Haass, 2000; diagnosis of probable AD was made according to the NINCDS-
Selkoe, 2001, 2002; Walter et al., 2001; Hardy and Selkoe ADRDA criteria (McKhann et al., 1984), clinically relevant other dis-
eases were excluded. MRI was done to exclude structural causes2002; Golde, 2003; Ingelsson and Hyman, 2002; Domin-
of dementia. Patients with mild to moderate dementia (MMSE 21.0guez and De Strooper, 2002; Sisodia and St. George-
3.2, range 16–26; Folstein et al., 1975) and with disease durationsHyslop, 2002). In analogy to infectious disease, where
of 3.6  2.3 years (range 1–11) were included. To exclude vascularthe primary role in causing disease is played by an infec-
dementia, Rosen Modified Ischemic scores were5. The mean age
tious agent, the characterization of the pathogenic role was 72.1  7.2 years (range 52–82). Patients were randomized in a
of -amyloid can be accomplished by two complemen- double-blind study design: 24 patients received an active vaccine
consisting of preaggregated synthetic A42 along with QS-21 adju-tary experiments: transmission and vaccination. Trans-
vant, and 6 patients received placebo. Both active vaccine andmission experiments are designed to identify the dis-
placebo were given as a prime intramuscular injection, followed 1ease-causing entity in a diseased tissue by isolating
month later by a boost intramuscular injection. The drug/placebothe minimal disease-causing entity, transmitting it to a
status remained blinded to patients, caregivers, clinical raters, and
healthy animal, and thereby causing the disease pheno- laboratory investigators. One patient from the placebo group died
type. For -amyloid, this was largely accomplished by during the study from cerebrovascular hemorrhage. One patient
refused testing at month 12. Therefore, our study ended with 28showing its role in neurofibrillar degeneration and in NFT
observed cases after one year. The 20 patients (6 female) who gener-formation, either by intracerebral microinjection or by
ated antibodies against -amyloid plaques were 73.6  7.0 yearstransgenic expression (Go¨tz et al., 2001; Lewis et al.,
old, had baseline MMSE scores of 21.6  3.2, and had a mean2001). Vaccination provides a complementary approach
duration of disease of 3.6  2.4 years. Nineteen (6 female) of these
to explore the role of a suspected disease-causing en- completed the study (age 73.4  7.1 years, MMSE 21.3  3.1,
tity. The experiment uses significant parts of the suspect duration 3.6  2.5 years). The 10 control patients (3 female) were
68.8  6.8 years old, had baseline MMSE scores of 19.9  3.2, andas a vaccine to induce antibody-mediated immunity in
had a mean duration of disease of 3.8  2.3 years. Nine (3 female)a host animal. If the generated antibodies selectively
of these completed the study (age 68.8  7.2 years, MMSE 19.2 react with the suspect and protect against disease—
2.5, duration 3.4  2.2 years).after exposure to an otherwise pathogenic dose of the
Twenty-eight patients received stable doses of AChEI for at least
suspected disease-causing entity—a central patho- 3 months prior to inclusion. AChEI were continued throughout the
genic role of the suspect is highly likely. From this point study, except for one patient who generated antibodies against
-amyloid and who terminated AChEI at month 11. The length ofof view, the use of -amyloid as a vaccine tests the
treatment with AChEI prior to testing at month 12 was similar amongpossibility that -amyloid plays a central role in causing
the patient groups with strong increases in TAPIR scores (3.0  2.2cognitive decline in AD. Our result that precisely the
years), with intermediate increases (2.1  0.8), or without increasespatients who developed antibodies against -amyloid—
(3.6  1.9; p  0.211, Kruskal-Wallis test). These time periods are
but not patients without such antibodies—prevented the beyond the 1 year period of known stabilizing effects of AChEI
progression of AD provides, therefore, the first success- (Doody et al., 2001; Giacobini, 2000). Of the patients who generated
antibodies against -amyloid, six received donepezil (5 mg per day,ful clinical evidence for a central role of -amyloid in
n  1; 10 mg, n  5), two rivastigmine (12 mg, n  1; 3 mg, n  1),causing cognitive decline and dementia in AD patients.
and eleven galantamine (16 mg, n  5; 24 mg, n  6). One patientThe fact that the degree of the protective effects was
changed from galantamine (16 mg) to rivastigmine (6 mg). Amongrelated to the magnitude of the immune response
control patients, five received donepezil (10 mg, n  5), four galan-
against -amyloid plaques in brain tissue underscores tamine (16 mg, n  1, 24 mg, n  3), and one patient no AChEI.
this conclusion. Other medications for cognitive enhancement were neither permit-
ted within the trial nor during the 3 month period prior to inclusion.Important open questions include the relationship of
Nonsteroidal antiinflammatory drugs (NSAID), statins, estrogens,the clinical efficacy to effects of antibodies against
and vitamin E were evenly distributed among the two groups. Pa--amyloid on the histopathology of AD. The initial obser-
tients who generated antibodies against -amyloid used NSAIDsvation of a single immunized case devoid of -amyloid
(n  11), statins (n  3) vitamin E (n  2), and no estrogens; patients
(Nicoll et al., 2003) is clearly supportive of antibody- in the control group used NSAIDs (n  5), statins (n  2), vitamin E
mediated removal of -amyloid, but additional his- (n  1), and estrogens (n  2).
topathological analyses are required to conclusively
confirm that removal of -amyloid from brain is both
Tissue Amyloid Plaque Immunoreactivity (TAPIR) Assay
necessary and sufficient for clinical efficacy. For the assessment of the ability of the human immune sera to react
In conclusion, our findings establish that antibodies with bona fide -amyloid plaques in brain tissue, we developed a
specific TAPIR assay. Double transgenic mice (18 months) express-against -amyloid plaques can slow clinical and cogni-
ing pathogenic AD-causing human mutant APP and PS1 genestive decline in patients with AD, and they indicate major
(APPswxPS1M146L) were perfused and fixed. Paraffin-embeddedadvantages of TAPIR assays over ELISA to predict clini-
brains sections were incubated with human sera or CSF taken atcal outcome. Our analyses should be continued by long-
baseline (month 0) and 56.0  5.8 days after the booster injection.
term follow-up studies of the complete cohort of AD Samples were used either undiluted or diluted 1:50 to 1:10,000 in
patients who generated antibodies against -amyloid 2% BSA and 10% horse serum in PBS. After washing, human IgG
bound to -amyloid plaques were detected with cy3-conjugatedas a result of A immunization.
donkey antibodies directed against heavy and light chains of human
IgG (Jackson Labs, Bar Harbor, Maine). Fluorescent secondary anti-Experimental Procedures
bodies were imaged through a 40 objective and a TRITC filter
attached to a Nikon Eclipse E800 fluorescence microscopePatients and Treatments
These experiments were done within an additional adjunct study of equipped with a Kappa PS 30C CCD camera. Images of all dilutions
were acquired with standardized camera settings chosen to be wellthe Zurich cohort of 30 AD patients (9 female) who participated in
-Amyloid Antibodies Slow Decline in Alzheimer’s
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below the saturation of 255 arbitrary units (A.U.) in 8 bit mode. Statistical Analyses
Data were analyzed by ANOVA. Comparisons of two groups wereThe Image J software (http://www.ncbi.nlm.nih.gov) was used to
quantify the mean pixel intensities (range 20 to 230 A.U.) of n  15 done with Mann-Whitney U tests, and comparisons of three groups
were done by Kruskal-Wallis tests. The distribution of categorical-amyloid plaques per serum dilution. Averages of the means were
used for both the standard curve and the individual samples. The variables between groups was tested by using the chi-square and
Fisher’s exact tests. The correlation coefficient quoted is Spear-assay was linear for serum dilutions ranging from 1:50 to 1:10,000
(r  0.951; p  0.013). man’s rho. All p values reported are two-sided. Changes in neuro-
psychological test scores (three data collection time points) wereFor comparisons with a standard curve obtained by diluting hu-
man CSF from a responder, both preimmune and immune sera were analyzed by observed cases analyses (OC). Changes in serum titers
and plasma A levels (ten data collection time points) were analyzedused at 1:50 dilutions and categorized by two independent, blinded
raters into the following five immunoreactivity scores: absent immu- by intention to treat (ITT) analysis; missing values were interpolated
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